跳至主要内容
临床试验/NCT03683017
NCT03683017Unknown不适用

OrthoPulse 2.0 and 2.1 Product Evaluation and Assessing Clinical Effectiveness: A Feasibility Study

Biolux Research Holdings, Inc.11 个研究点 分布在 2 个国家目标入组 35 人开始时间: 2017年12月22日最近更新:
适应症
干预措施

试验速览

阶段
不适用
发起方
入组人数
35
试验地点
11
主要终点
Feedback on general experience

研究概览

简要总结

OrthoPulse is a device that uses near-infrared light therapy in order to decrease orthodontic treatment time. The aim of this study is to evaluate OrthoPulse products modified with extended arrays, OrthoPulse 2.0 and OrthoPulse 2.1, and to assess their clinical effectiveness.

研究设计

研究类型
Interventional
分配方式
Non Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
11 Years 至 —(Child, Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Written Informed Consent must be obtained before any assessment is performed
  • Patient must be 11 years of age or older; minors will only be included in the study with the consent of the Parent/Legal Authorized Representative (LAR)
  • Presence of permanent dentition
  • Eligible and scheduled for full mouth fixed orthodontic treatment or Invisalign
  • Good oral hygiene
  • Likely to be compliant to OrthoPulse 2.0 and 2.1 use, aligner wear and elastic wear
  • Have a compatible iOS or Android device and are willing to download the OrthoPulse app for frequent automatic syncing of use data

排除标准

  • Patient is currently enrolled in another clinical study
  • Periodontally involved teeth, acute oral infection or periodontal disease
  • Use of bisphosphonates (osteoporosis drugs) during the study
  • Use of drugs that may cause photosensitivity
  • History of photosensitivity
  • History of poor oral hygiene, per the discretion of the Principal Investigator (PI)
  • Patient plans to relocate over the treatment period
  • Smoker or use of any tobacco containing products per the discretion of the PI

研究组 & 干预措施

I-OP2.0

Experimental

Patients receive Invisalign orthodontic treatment, with 3.5 day Aligner changes, by the qualified Principal Investigator (PI). Patients receive OrthoPulse 2.0 device.

干预措施: OrthoPulse 2.0 (Device)

I-OP2.0

Experimental

Patients receive Invisalign orthodontic treatment, with 3.5 day Aligner changes, by the qualified Principal Investigator (PI). Patients receive OrthoPulse 2.0 device.

干预措施: Invisalign 3.5 Day Wear (Device)

I-OP2.1

Experimental

Patients receive Invisalign orthodontic treatment, with 3.5 day Aligner changes, by the qualified Principal Investigator (PI). Patients receive OrthoPulse 2.1 device.

干预措施: OrthoPulse 2.1 (Device)

I-OP2.1

Experimental

Patients receive Invisalign orthodontic treatment, with 3.5 day Aligner changes, by the qualified Principal Investigator (PI). Patients receive OrthoPulse 2.1 device.

干预措施: Invisalign 3.5 Day Wear (Device)

F-OP2.0

Experimental

Patients receive fixed appliance orthodontic treatment by the qualified Principal Investigator (PI). Patients receive OrthoPulse 2.0 device.

干预措施: OrthoPulse 2.0 (Device)

F-OP2.0

Experimental

Patients receive fixed appliance orthodontic treatment by the qualified Principal Investigator (PI). Patients receive OrthoPulse 2.0 device.

干预措施: Fixed Orthodontic Appliances (Braces) (Device)

结局指标

主要结局

Feedback on general experience

时间窗: Through Study Completion, approx. 2 years

Assess doctor and patient feedback on the general experience with OrthoPulse 2.0 and OrthoPulse 2.1 as measured in the electronic data capture system.

Feedback on clinical performance

时间窗: Through Study Completion, approx. 2 years

Assess doctor subjective and objective feedback on the clinical performance of OrthoPulse 2.0 and OrthoPulse 2.1 as measured in the electronic data capture system.

Adverse events

时间窗: Through Study Completion, approx. 2 years

Confirm initial safety of OrthoPulse 2.0 and OrthoPulse 2.1

次要结局

未报告次要终点

研究者

发起方
Biolux Research Holdings, Inc.
申办方类型
Industry
责任方
Sponsor

研究点 (11)

Loading locations...

相似试验